C-MYC ALL NHL FISH Test: Advanced Genetic Cancer Detection
Understanding the C-MYC ALL NHL FISH Test
The C-MYC ALL NHL FISH test represents a cutting-edge molecular diagnostic approach that utilizes fluorescence in situ hybridization (FISH) technology to detect specific genetic abnormalities in the C-MYC gene. This gene plays a pivotal role in regulating cell growth and division, and when disrupted, can lead to the development of aggressive forms of leukemia and lymphoma. The test provides critical information that helps oncologists make informed decisions about treatment strategies and prognosis assessment.
What Does the C-MYC ALL NHL Test Measure?
This sophisticated genetic test specifically targets and analyzes:
- C-MYC Gene Rearrangements: Detects translocations involving the C-MYC gene on chromosome 8
- Gene Amplifications: Identifies increased copies of the C-MYC gene that drive cancer progression
- Chromosomal Abnormalities: Analyzes structural changes that affect C-MYC gene function
- Oncogene Activation: Assesses the activation status of this critical cancer-promoting gene
Who Should Consider This Test?
The C-MYC ALL NHL FISH test is particularly important for individuals experiencing:
- Suspected or diagnosed acute lymphoblastic leukemia (ALL)
- Non-Hodgkin lymphoma (NHL) with aggressive features
- Rapidly progressing blood cancers requiring urgent diagnosis
- Patients with treatment-resistant leukemia or lymphoma
- Individuals requiring prognostic information for treatment planning
- Patients being evaluated for targeted therapy options
Clinical Benefits of C-MYC Testing
Undergoing the C-MYC ALL NHL FISH test provides numerous advantages:
- Accurate Diagnosis: Precise identification of C-MYC abnormalities for definitive diagnosis
- Prognostic Information: Assessment of disease aggressiveness and likely progression
- Treatment Guidance: Information to help select the most effective therapeutic approaches
- Disease Monitoring: Baseline data for tracking treatment response and disease evolution
- Risk Stratification: Classification of patients into appropriate risk categories
- Personalized Medicine: Foundation for tailored treatment strategies based on genetic profile
Understanding Your Test Results
Your C-MYC ALL NHL FISH test results will be carefully interpreted by our expert genetic specialists:
- Positive Result: Indicates the presence of C-MYC gene abnormalities, suggesting aggressive disease that may require intensive treatment
- Negative Result: No C-MYC abnormalities detected, which may indicate standard-risk disease
- Complex Findings: Multiple genetic changes that require comprehensive interpretation
- Quantitative Analysis: Assessment of the extent of C-MYC gene involvement
All results include detailed explanations and clinical recommendations from our board-certified oncologists and genetic counselors.
Test Information and Pricing
| Test Parameter | Details |
|---|---|
| Test Name | C-MYC ALL NHL FISH Test |
| Regular Price | $176 USD |
| Discount Price | $132 USD |
| Turnaround Time | 3-4 Days |
| Sample Type | Bone Marrow / Peripheral Blood |
| Test Components | Sodium Heparin Vacutainer (2ml) |
| Methodology | Fluorescence In Situ Hybridization (FISH) |
Nationwide Testing Availability
GGC DNA maintains comprehensive testing facilities across the United States, with convenient locations in major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our state-of-the-art laboratories ensure consistent, high-quality results regardless of your location.
Book Your C-MYC ALL NHL FISH Test Today
Take control of your health journey with advanced genetic cancer testing. Our experienced team is ready to provide you with the critical information needed for optimal cancer management. Contact us today to schedule your test or speak with our genetic counseling specialists.
Call or WhatsApp: +1(267) 388-9828
Note: The C-MYC ALL NHL FISH test requires a doctor’s prescription. Prescription requirements do not apply for surgical cases, pregnancy-related testing, or individuals planning international travel.
